

# Paul M Mckeigue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4893355/publications.pdf>

Version: 2024-02-01

60  
papers

2,339  
citations

270111

25  
h-index

274796

44  
g-index

75  
all docs

75  
docs citations

75  
times ranked

5368  
citing authors

#	ARTICLE	IF	CITATIONS
1	Flash monitor initiation is associated with improvements in HbA1c levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study. <i>Diabetologia</i> , 2022, 65, 159-172.	2.9	12
2	Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 566-572.	5.2	23
3	Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland. <i>Scandinavian Journal of Rheumatology</i> , 2022, , 1-6.	0.6	2
4	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. <i>Nature Medicine</i> , 2022, 28, 1256-1268.	15.2	105
5	Quantitative levels of serum N-glycans in type 1 diabetes and their association with kidney disease. <i>Glycobiology</i> , 2021, 31, 613-623.	1.3	6
6	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 82-93.	5.5	251
7	Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study. <i>BMC Medicine</i> , 2021, 19, 51.	2.3	41
8	The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 1309-1319.	2.9	5
9	Sharing a household with children and risk of COVID-19: a study of over 300 000 adults living in healthcare worker households in Scotland. <i>Archives of Disease in Childhood</i> , 2021, 106, 1212-1217.	1.0	36
10	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. <i>Diabetologia</i> , 2021, 64, 1320-1331.	2.9	19
11	Microvascular disease in diabetes and severe COVID-19 outcomes – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 201.	5.5	0
12	Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study. <i>BMC Medicine</i> , 2021, 19, 149.	2.3	26
13	Development and validation of a cardiovascular risk prediction model in type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 2001-2011.	2.9	22
14	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. <i>Diabetes Care</i> , 2021, 44, 2010-2017.	4.3	8
15	Risk of hospital admission with covid-19 among teachers compared with healthcare workers and other adults of working age in Scotland, March 2020 to July 2021: population based case-control study. <i>BMJ</i> , 2021, 374, n2060.	3.0	23
16	Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. <i>Diabetes Care</i> , 2021, 44, 390-398.	4.3	55
17	Association of cerebral venous thrombosis with recent COVID-19 vaccination: case-crossover study using ascertainment through neuroimaging in Scotland. <i>BMC Infectious Diseases</i> , 2021, 21, 1275.	1.3	13
18	Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. <i>Diabetologia</i> , 2020, 63, 788-798.	2.9	31

#	ARTICLE	IF	CITATIONS
19	Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. <i>Diabetologia</i> , 2020, 63, 636-647.	2.9	22
20	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003374.	3.9	61
21	Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between <i>IL18RAP</i> expression and treatment response. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1446-1452.	0.5	13
22	Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. <i>BMJ</i> , The, 2020, 371, m3582.	3.0	261
23	Biomarkers associated with early stages of kidney disease in adolescents with type 1 diabetes. <i>Pediatric Diabetes</i> , 2020, 21, 1322-1332.	1.2	9
24	Diabetic Neuropathy Is a Substantial Burden in People With Type 1 Diabetes and Is Strongly Associated With Socioeconomic Disadvantage: A Population-Representative Study From Scotland. <i>Diabetes Care</i> , 2020, 43, 734-742.	4.3	22
25	Time trends in deaths before age 50 years in people with type 1 diabetes: a nationwide analysis from Scotland 2004-2017. <i>Diabetologia</i> , 2020, 63, 1626-1636.	2.9	6
26	Prediction of colorectal cancer risk based on profiling with common genetic variants. <i>International Journal of Cancer</i> , 2020, 147, 3431-3437.	2.3	17
27	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology's Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) <a href="#">Tj ETQq1 10:7843147gBT /Ove</a>	4.3	13
28	Expression quantitative trait loci-derived scores and white matter microstructure in UK Biobank: a novel approach to integrating genetics and neuroimaging. <i>Translational Psychiatry</i> , 2020, 10, 55.	2.4	8
29	Title is missing!. , 2020, 17, e1003374.		0
30	Title is missing!. , 2020, 17, e1003374.		0
31	Title is missing!. , 2020, 17, e1003374.		0
32	Title is missing!. , 2020, 17, e1003374.		0
33	Title is missing!. , 2020, 17, e1003374.		0
34	Quantifying performance of a diagnostic test as the expected information for discrimination: Relation to the <i>C</i> -statistic. <i>Statistical Methods in Medical Research</i> , 2019, 28, 1841-1851.	0.7	19
35	Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization study. <i>PLoS Medicine</i> , 2019, 16, e1002937.	3.9	81
36	Use of personalised risk-based screening schedules to optimise workload and sojourn time in screening programmes for diabetic retinopathy: A retrospective cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002945.	3.9	12

#	ARTICLE	IF	CITATIONS
37	Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. <i>BMC Medicine</i> , 2019, 17, 165.	2.3	43
38	Phenome-wide Mendelian-randomization study of genetically determined vitamin D on multiple health outcomes using the UK Biobank study. <i>International Journal of Epidemiology</i> , 2019, 48, 1425-1434.	0.9	61
39	Biomarker panels associated with progression of renal disease in type 1 diabetes. <i>Diabetologia</i> , 2019, 62, 1616-1627.	2.9	41
40	Glycaemic control trends in people with type 1 diabetes in Scotland 2004-2016. <i>Diabetologia</i> , 2019, 62, 1375-1384.	2.9	45
41	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and <i>CD39</i> . <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1055-1061.	0.5	25
42	Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1400-1409.	0.9	39
43	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. <i>Diabetologia</i> , 2019, 62, 621-632.	2.9	33
44	Serum kidney injury molecule 1 and $\beta$ 2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes. <i>Diabetologia</i> , 2019, 62, 156-168.	2.9	50
45	Sample size requirements for learning to classify with high-dimensional biomarker panels. <i>Statistical Methods in Medical Research</i> , 2019, 28, 904-910.	0.7	9
46	MR-PheWAS: exploring the causal effect of SUA level on multiple disease outcomes by using genetic instruments in UK Biobank. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1039-1047.	0.5	57
47	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1414-1427.	0.3	136
48	N-Glycan Profile and Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 79-87.	4.3	75
49	Prediction of treatment response in rheumatoid arthritis patients using genome-wide SNP data. <i>Genetic Epidemiology</i> , 2018, 42, 754-771.	0.6	15
50	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2018, 18, 657-664.	0.9	41
51	GenImp: Fast Imputation to Large Reference Panels Using Genotype Likelihoods from Ultralow Coverage Sequencing. <i>Genetics</i> , 2017, 206, 91-104.	1.2	38
52	Automated pathway and reaction prediction facilitates in silico identification of unknown metabolites in human cohort studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1071, 58-67.	1.2	16
53	Modelling cumulative exposure for inference about drug effects in observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1527-1533.	0.9	7
54	GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk. <i>Nature Communications</i> , 2017, 8, 1584.	5.8	61

#	ARTICLE	IF	CITATIONS
55	The Genetic Landscape of Renal Complications in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2017, 28, 557-574.	3.0	101
56	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	1.5	28
57	Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney International, 2015, 88, 888-896.	2.6	124
58	Extending Admixture Mapping to Nuclear Pedigrees: Application to Sarcoidosis. Genetic Epidemiology, 2013, 37, 256-266.	0.6	6
59	Efficacy of COVID-19 vaccination in individuals designated as clinically extremely vulnerable in Scotland. F1000Research, 0, 10, 663.	0.8	2
60	Fitting joint models of longitudinal observations and time to event by sequential Bayesian updating. Statistical Methods in Medical Research, 0, , 096228022211042.	0.7	0